Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment

International Journal of Clinical Practice

Volumn 60, Issue 6, 2006, Pages 707-715

  Oberwittler, H ^a   Baccara Dinet, Marie ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Dohme Chibret Centre de Recherche Riom   (France)

Author keywords

Acetylsalicylic acid; Discontinuation; Flushing; Nicotinic acid

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; COLESTYRAMINE; CYCLOOXYGENASE 1 INHIBITOR; DICLOFENAC; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INDOMETACIN; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; NICOTINIC ACID; NIFLUMIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PRAVASTATIN; PROSTAGLANDIN; SIMVASTATIN;

CLINICAL PROTOCOL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE CONTROL; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; DRUG USE; DRUG WITHDRAWAL; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; FLUSHING; HEALTH SURVEY; HUMAN; HYPERTENSION; INCIDENCE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PRURITUS; REVIEW; SIDE EFFECT; SKIN TINGLING;

EID: 33744516859     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2006.00957.x     Document Type: Review

References (65)

1. McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med 2004; 164: 697-705.
2. Soga T, Kamohara M, Takasaki J et al. Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun 2003; 303: 364-9.
3. Tunaru S, Kero J, Schaub A et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 2003; 9: 352-5.
4. Wise A, Foord SM, Fraser NJ et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 2003; 278: 9869-74.
5. Karpe F, Frayn KN. The nicotinic acid receptor - a new mechanism for an old drug. Lancet 2004; 363: 1892-4.
6. Pike NB, Wise A. Identification of a nicotinic acid receptor. is that the molecular target for the oldest lipid-lowering drug? Curr Opin Investig Drugs 2004; 5: 271-5.
7. Rubic T, Trottmann M, Lorenz RL. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol 2004; 67: 411-9.
8. Altschul R. Niacin in vascular disorders and hyperlipemia. Altschul R, ed. IL, USA: CharlPs C Thomas, 1964: pp 3-135.
9. Svedmyr N, Harthon L, Lundholm L. The relationship between the plasma concentration of free nicotinic acid and some of its pharmacologic effects in man. Clin Pharmacol Ther 1969; 10: 559-70.
10. Åberg G, Svedmyr N. Thermographic registration of flush. Arzneimittelforschung 1971; 21: 795-6.
11. Åberg G. Inhibition of flush induced by nicotinic acid. Int Res Commun 1973; 1: 13.
12. Andersson RG, Aberg G, Brattsand R et al. Studies on the mechanism of flush induced by nicotinic acid. Acta Pharmacol Toxicol (Copenh) 1977; 41: 1-10.
13. Morrow JD, Awad JA, Oates JA, Roberts LJ. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J Invest Dermatol 1992; 98: 812-5.
14. Saareks V, Mucha I, Sievi E, Riutta A. Nicotinic acid and pyridoxine modulate arachidonic acid metabolism in vitro and ex vivo in man. Pharmacol Toxicol 1999; 84: 274-80.
15. BenyóZ, Gille A, Kero J et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest 2005; 115: 3634-40.
16. Whelan AM, Price SO, Fowler SF, Hainer BL. The effect of aspirin on niacin-induced cutaneous reactions. J Fam Pract 1992; 34: 165-8.
17. McKenney J. Niacin for dyslipidemia: Considerations for product selection. Am J Health Syst Pharm 2003; 60: 995-1005.
18. Iwaki M, Ogiso T, Hayashi H et al. Acute dose-dependent disposition studies of nicotinic acid in rats. Drug Metab Dispos 1996; 24: 773-9.
19. Ding RW, Kolbe K, Merz B et al. Pharmacokinetics of nicotinic acid-salicylic acid interaction. Clin Pharmacol Ther 1989; 46: 642-7.
20. Piepho RW. The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. Am J Cardiol 2000; 86 (Suppl.): 35L-40L.
21. Pieper JA. Overview of niacin formulations. differences in pharmacokinetics, efficacy, and safety. Am J Health Syst Pharm 2003; 60: S9-S14.
22. Jungnickel PW, Maloley PA, Vander Tuin EL et al. Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions. J Gen Intern Med 1997; 12: 591-6.
23. Wilkin JK, Wilkin O, Kapp R et al. Aspirin blocks nicotinic acid-induced flushing. Clin Pharmacol Ther 1982; 31: 478-82.
24. Dunn RT, Ford MA, Rindone JP, Kwiecinski FA. Low-dose aspirin and ibuprofen reduce the cutaneous reactions following niacin administration. Am J Ther 1995; 2: 478-80.
25. Knopp RH, Ginsberg J, Albers JJ et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: Clues to mechanism of action of niacin. Metabolism 1985; 34: 642-50.
26. Keenan JM, Fontaine PL, Wenz JB et al. Niacin revisited. A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia. Arch Intern Med 1991; 151: 1424-32.
27. Jacobson TA, Chin MM, Fromell GJ et al. Fluvastatin with and without niacin for hypercholesterolemia. Am J Cardiol 1994; 74: 149-54.
28. Tsalamandris C, Panagiotopoulos S, Sinha A et al. Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients. J Cardiovasc Risk 1994; 1: 231-9.
29. Davignon J, Roederer G, Montigny M et al. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol 1994; 73: 339-45.
30. Gardner SF, Marx MA, White LM et al. Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control. Ann Pharmacother 1997; 31: 677-82.
31. Rindone JP, Arriola OG. Experience with crystalline niacin as the preferred drug for dyslipidemia in a specialty clinic. Pharmacotherapy 1997; 17: 1296-9.
32. Capuzzi DM, Guyton JR, Morgan JM et al. Efficacy and safety of an extended-release niacon (Niaspan): A long-term study. Am J Cardiol 1998; 82: 74U-81U.
33. Knopp RH, Alagona P, Davidson M et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998; 47: 1097-104.
34. Guyton JR, Goldberg AC, Kreisberg RA et al. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 1998; 82: 737-43.
35. Garg R, Elam MB, Crouse JR III et al. Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. Am Heart J 2000; 140: 792-803.
36. Guyton JR, Blazing MA, Hagar J et al. Extended release niacin vs gemfibrozil for the treatment of low levels of high density lipoprotein cholesterol. Arch Intern Med 2000; 160: 1177-84.
37. Goldberg A, Alagona P Jr, Capuzzi DM et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 2000; 85: 1100-5.
38. McKenney JM, McCormick LS, Schaefer EJ et al. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol 2001; 88: 270-4.
39. Grundy SM, Vega GL, McGovern ME et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: Results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial. Arch Intern Med 2002; 162: 1568-76.
40. Pan J, Lin M, Kesala RL et al. Niacin treatment of the atherogenic lipid profile and Lp (a) in diabetes. Diabetes Obes Metab 2002; 4: 255-61.
41. Kashyap ML, McGovern ME, Berra K et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002; 89: 672-8.
42. Bays HE, Dujovne CA, McGovern ME et al. ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol 2003; 91: 667-72.
43. Hunninghake DB, McGovern ME, Koren M et al. A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin. Clin Cardiol 2003; 26: 112-8.
44. Morgan JM, Capuzzi DM, Baksh RI et al. Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol 2003; 91: 1432-6.
45. Rubenfire M, Impact of Medical Subspecialty on Patient Compliance to Treatment Study Group. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study. Am J Cardiol 2004; 94: 306-11.
46. Insull W Jr, McGovern ME, Schrott H et al. Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: Assessing all reasonable doses with innovative surface graph analysis. Arch Intern Med 2004; 164: 1121-7.
47. Zhao XQ, Morse JS, Dowdy AA et al. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). Am J Cardiol 2004; 93: 307-12.
48. Wink J, Giacoppe G, King J. Effect of very-low-dose niacin on high-density lipoprotein in patients undergoing long-term statin therapy. Am Heart J 2002; 143: 514-8.
49. Whitney EJ, Krasuski RA, Personius BE et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 2005; 142: 95-104.
50. Taylor AJ, Sullenberger LE, Lee HJ et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2. Circulation 2004; 110: 3512-7.
51. Brown G, Albers JJ, Fisher LD et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289-98.
52. Ryan MJ Jr, Gibson J, Simmons P, Stanek E. Effectiveness of aggressive management of dyslipidemia in a collaborative-care practice model. Am J Cardiol 2003; 91: 1427-31.
53. Brown BG, Zhao XQ, Chait A. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 1583-92.
54. Elam MB, Hunninghake DB, Davis KB et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral Arterial disease: The ADMIT study: a randomized trial. Arterial Dis Multiple Intervention Trial. JAMA 2000; 284: 1263-70.
55. Gentile S, Rubba P, Persico M et al. Improvement of the nicotinic acid test in the diagnosis of Gilbert's syndrome by pretreatment with indomethacin. Hepatogastroenterology 1985; 32: 267-9.
56. Duteil L, Queille C, Poncet M et al. Objective assessment of topical corticosteroids and non-steroidal anti-inflammatory drugs in methyl-nicotinate-induced skin inflammation. Clin Exp Dermatol 1990; 15: 195-9.
57. Saareks V, Ylitalo P, Mucha I, Riutta A. Opposite effects of nicotinic acid and pyridoxine on systemic prostacyclin, thromboxane and leukotriene production in man. Pharmacol Toxicol 2002; 90: 338-42.
58. Cholesterol Adult Treatment Panel. Report of the national education program expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Arch Intern Med 1988; 148: 36-9.
59. Coronary Drug Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 360-81.
60. Luria MH. Effect of low-dose niacin on high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol ratio. Arch Intern Med 1988; 148: 2493-5.
61. Schectman G, Hiatt J, Hartz A. Evaluation of the effectiveness of lipid-lowering therapy (bile acid sequestrants, niacin, psyllium and lovastatin) for treating hypercholesterolemia in veterans. Am J Cardiol 1993; 71: 759-65.
62. Illingworth DR, Stein EA, Mitchel YB et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med 1994; 154: 1586-95.
63. McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA 1994; 271: 672-7.
64. Martin-Jadraque R, Tato F, Mostaza JM et al. Effectiveness of low-dose crystalline nicotinic acid in men with low high-density lipoprotein cholesterol levels. Arch Intern Med 1996; 156: 1081-8.
65. US prescribing information on line. http://www.niaspan.com (accessed on October 10 2005).